Overview

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Camptothecin
Irinotecan
Panitumumab